Why IM Cannabis Corp. (NASDAQ:IMCC) Is In Focus Now?
IM Cannabis Corp. (IMCC) draws attention after a current business development reshapes the market discussion around operations, customers, competition, and sector conditions ...
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Im Cannabis Corp. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Im Cannabis Corp. is a small-cap company with a market capitalization of $2M. It ranks number 26 by market capitalization among the 29 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For IMCC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -43.0%, measured on 322 forecast dates between 2023-03-31 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -12.0%, measured on 365 forecast dates between 2023-03-31 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, IMCC included.
Follow IMCC free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric. Statement values were filed in CAD and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
| Metric | IMCC | Rank |
|---|---|---|
| Market Cap | $2M | 26/29 |
| EPS | $-3.99 | – |
| Revenue/Share | $59.25 | – |
| FCF/Share | $3.38 | – |
| Metric | IMCC | Rank |
|---|---|---|
| Gross Margin | 16.4% | 20/23 |
| Operating Margin | -18.4% | 15/24 |
| EBT Margin | -21.3% | 16/25 |
| Tax Rate | 6.2% | – |
| Metric | IMCC | Rank |
|---|---|---|
| Current Ratio | 0.67x | 21/29 |
| Quick Ratio | 0.54x | 15/26 |
| Working Capital | -$8M | 27/29 |
| Metric | IMCC | Rank |
|---|---|---|
| Operating Cash Flow | $6M | 10/30 |
| Free Cash Flow | $6M | 8/12 |
| Capital Spending | -$160K | 2/12 |
| FCF Growth YoY | 0.0% | 3/6 |
| FCF/Sales | 5.7% | 5/12 |
| CapEx/Sales | 0.2% | 11/12 |
| Metric | IMCC | Rank |
|---|---|---|
| Asset Turnover | 4.29x | 1/17 |
| Receivables Turnover | 31.6x | 3/16 |
| Inventory Turnover | 26.7x | 1/21 |
| Fixed Assets Turnover | 36.7x | 4/17 |
| Days Sales Outstanding | 12 days | 14/16 |
| Days Inventory | 14 days | 20/20 |
| Metric | IMCC | Rank |
|---|---|---|
| Total Revenue | $98M | 14/18 |
| Operating Income | -$18M | 20/28 |
| Cost of Goods Sold | $82M | 8/24 |
| Metric | IMCC | Rank |
|---|---|---|
| Shares Outstanding | 2M | – |
| Total Current Assets | $17M | 71.6% of assets |
| Cash & Short-term Investments | $2M | 8.6% of assets |
| Accounts Receivable | $3M | 13.6% of assets |
| Inventory | $3M | 13.4% of assets |
| Total Liabilities | $26M |
Companies classified under the same SEC industry code as Im Cannabis Corp. (Medicinal Chemicals & Botanical Products): 33 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| IMCC Im Cannabis Corp. | ▼ | $2M |
| DFTX Definium Therapeutics, Inc. | ▲ | $4.31B |
| TRLV Trulieve Cannabis Corp. | ▲ | $1.93B |
| CRON Cronos Group Inc. | ▶ | $1.18B |
| TLRY Tilray Brands, Inc. | ▼ | $414M |
| SNDL Sndl Inc. | ▶ | $322M |
| CGC Canopy Growth Corp | ▶ | $302M |
| GLAS Glass House Brands Inc. | ▼ | $301M |
| USNA Usana Health Sciences Inc | ▼ | $287M |
| ACB Aurora Cannabis Inc | ▶ | $253M |
| NAGE Niagen Bioscience, Inc. | ▶ | $197M |
| MDWD Mediwound Ltd. | ▶ | $152M |
| AAWH Ascend Wellness Holdings, Inc. | ▲ | $80M |
| FTLF Fitlife Brands, Inc. | ▲ | $79M |
| BTMD Biote Corp. | ▲ | $35M |
| RAPH Raphael Pharmaceutical Inc. | ▼ | $30M |
| CHUC Charlie's Holdings, Inc. | ▼ | $27M |
| MRMD Marimed Inc. | ▲ | $24M |
| CFOO China Foods Holdings Ltd. | ▼ | $21M |
| MTEX Mannatech Inc | ▲ | $14M |
| ADIA Adia Med, Inc. | ▲ | $13M |
| GLUC Glucose Health, Inc. | ▼ | $9M |
| NAII Natural Alternatives International Inc | ▲ | $7M |
| BON Bon Natural Life Ltd | ▶ | $7M |
| PLSH Panacea Life Sciences Holdings, Inc. | ▲ | $6M |
| CYAN Cyanotech Corp | ▲ | $5M |
| AIBT Aibotics, Inc. | ▼ | $2M |
| NPHC Nutra Pharma Corp | ▼ | $720K |
| MEHA Functional Brands Inc. | ▼ | $290K |
| CBDY Target Group Inc. | ▼ | N/A |
| HYEX Healthy Extracts Inc. | ▶ | N/A |
| NTRR Neutra Corp. | ▼ | N/A |
| SNYRQ Synergy Chc Corp. | ▼ | N/A |
IM Cannabis Corp. (IMCC) draws attention after a current business development reshapes the market discussion around operations, customers, competition, and sector conditions ...
TORONTO and GLIL YAM, Israel, June 18, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC), a medical cannabis company with operations in Israel and Germany, is pleased to ...
Good morning, and welcome to IM Cannabis’ First Quarter 2025 Earnings Conference Call. Today’s conference call is being recorded. At this time, I would like to turn the conference over to Anna Taranko ...
Our AI ranks Im Cannabis Corp. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For IMCC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -43.0%, measured on 322 forecast dates between 2023-03-31 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -12.0%, measured on 365 forecast dates between 2023-03-31 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Im Cannabis Corp. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
33 issuers in our coverage, IMCC included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Canopy Growth Corp (CGC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.